Thiourea derivatives of uracil were efficiently synthesized the reaction of 5-aminouracil with isothiocyanates. Then, we prepared uracil-containing thiazoles condensation of thioureas with diethyl/dimethyl acetylenedicarboxylates. The structures of the products were confirmed by a combination of spectral techniques including infra-red (IR), nuclear magnetic resonance (NMR), mass spectrometry (MS) and elemental analyses. A rationale for the formation of the products is presented. The newly synthesized compounds were evaluated for their antiproliferative activity against four cancer cell lines. The compounds tested showed promising antiproliferative activity, with GI values ranging from 1.10 µM to 10.00 µM. Compounds and were the most potent derivatives, with GI values ranging from 1.10 µM to 1.80 µM. Compound showed potent inhibitory activity against EGFR and BRAF with IC of 91 ± 07 and 93 ± 08 nM, respectively, indicating that this compound could serve as a dual inhibitor of EGFR and BRAF with promising antiproliferative properties. Docking computations revealed the great potency of compounds and towards EGFR and BRAF with docking scores of -8.3 and -9.7 kcal/mol and -8.2 and -9.3 kcal/mol, respectively.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792171 | PMC |
http://dx.doi.org/10.3389/fchem.2022.1076383 | DOI Listing |
Radiol Med
March 2025
Radiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Aim: Despite the widespread use of immunotherapy (IO) and targeted therapy (TT) in clinical practice, data on toxicity in combination with SBRT are lacking, largely based on retrospective studies and case reports. The present survey, conducted within the AIRO Oligometastatic Study Group, was developed for radiation oncologists to investigate the current clinical practice in Italy regarding hypofractionated SBRT (defined as a dose/fraction ≥ 5 Gy) in cancer patients using IO and TT.
Methods: The online survey, composed of 19 questions, was developed using the cloud-based platform SurveyMonkey® and was sent to all registered AIRO members using the association's mailing list and was administered online and in anonymous form.
Expert Opin Biol Ther
March 2025
AMGEN S.A, Barcelona, Spain.
Introduction: Adding monoclonal antibodies to chemotherapy drastically changed the landscape of advanced colorectal cancer. The prediction of benefit from anti-EGFR therapies is mainly based on the absence of mutations in RAS and BRAF genes, the primary tumor sidedness and microsatellite MSS/MSI status. Molecular hyperselection may optimize the outcome of patients receiving anti-EGFR while detecting additional resistance alterations, both in chemo-naïve and in chemo-refractory settings.
View Article and Find Full Text PDFBMC Cancer
March 2025
Department of Neurosurgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, 550000, China.
Background: Tumor mutation burden (TMB) is a predictive biomarker for assessing the response of various tumor types to immune checkpoint inhibitors (ICI). TMB is quantified based on somatic mutations identified by next-generation sequencing (NGS) using targeted panel data. This study aimed to investigate whether different NGS methods will affect the results of TMB detection in solid tumors.
View Article and Find Full Text PDFMol Divers
March 2025
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Novel quinoline-based derivatives 2a-e and 4a-j have been designed and synthesized as potential antiproliferative agents. The designed compounds were screened for their antiproliferative activity against sixty cell lines according to NCI protocol. The promising hybrids 4d-g are screened by MTT assays on three cancer cell lines: leukemia (MOLT-4), lung cancer (HOP-92), and breast cancer (T47D), with IC values ranging from 4.
View Article and Find Full Text PDFJ Neurooncol
March 2025
Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Purpose: Extra-central nervous system metastasis (ECM) from glioblastoma and other high-grade gliomas (HGGs) is exceedingly rare, likely due to central nervous system barriers and the short overall survival (OS) in HGG patients, limiting the timeframe for metastasis. Improved treatments have extended survival, potentially increasing ECM incidence, though mechanisms remain unclear.
Methods: This retrospective study examines HGG patients (n = 16) with ECM treated at The University of Texas M.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!